Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiac Pathways

This article was originally published in The Gray Sheet

Executive Summary

Ultrasound Tracking System computer system and catheters are expected to gain 510(k) clearance in late January-early February and March, respectively, the firm announces at AHA Nov. 8. The submissions were made in August. The system uses ultrasound transducers "to precisely triangulate, in real time, the position of the catheters within the heart during the diagnostic procedure," without the use of fluoroscopy, Cardiac Pathways explains. The firm plans to integrate the Tracking System with its Chilli cooled radiofrequency ablation catheter which received FDA premarket approval on Feb. 2 (1"The Gray Sheet" Feb. 8, p. 11)

You may also be interested in...



Chilli RF Ablation System Approval Broader Than Recommended By Panel

Cardiac Pathways Corporation's Chilli cooled ablation system, approved via premarket approval application Feb. 2, has received a much less restrictive indication from FDA than recommended by the agency's Circulatory System Devices Advisory Panel.

Cosmetic And Personal Care Trademark Review: 9 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012596

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel